Utah 2025 Regular Session

Utah House Bill HB0543

Introduced
2/24/25  

Caption

Controlled Substance Licensing Amendments

Impact

The implications of HB 543 are substantial, particularly in how they govern the prescribing of controlled substances. The bill mandates that prescribers offer to prescribe an opiate antagonist to patients receiving high doses of opiates, as well as engage in a thorough discussion with patients about the risks associated with these medications. With this requirement, the bill aims to enhance patient awareness and reduce the potential for addiction, thereby addressing the ongoing opioid crisis. Additionally, it includes provisions for the creation of electronic prescriptions to further streamline and regulate the process of prescribing controlled substances.

Summary

House Bill 543, known as the Controlled Substance Licensing Amendments, seeks to amend various provisions related to the licensure and regulation of controlled substances in the state. A significant component of the bill is the introduction of controlled substance certification for practitioners who wish to prescribe, dispense, or administer controlled substances. The bill stipulates that beginning July 1, 2025, practitioners must obtain this certification to distribute or dispense controlled substances, ensuring that they meet the necessary qualifications and training requirements established by the state.

Contention

Debate surrounding HB 543 has surfaced regarding concerns about the potential overreach into the longstanding physician-patient relationship. Critics argue that the requirement for prescribers to follow strict guidelines may hinder the movement of physicians in making individualized care decisions based on the context of their patient's needs. Furthermore, some members of the legislative discussions have pointed out that while the bill aims to combat addiction, the number of regulatory requirements could inadvertently create barriers for healthcare providers, especially those in rural or underserved areas who may find compliance challenging.

Companion Bills

No companion bills found.

Similar Bills

NJ A5488

Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances; requires reporting of xylazine prescriptions.

IL SB0647

HEALTH-TECH

AZ SB1447

Fentanyl; manufacturing drugs; machines

AZ SB1401

Hemp-derived manufactured impairing cannabinoids

VA SB591

Marijuana; shape productions, definitions.

KY HB764

AN ACT relating to the Kentucky All Schedule Prescription Electronic Reporting system.

KY HB389

AN ACT relating to prescription drugs.

VA HB2775

Hemp product; clarifies definition.